We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Iteos Therapeutics Inc
9 own
5 watching
Current Price
$9.84
$-0.07
(-0.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
540.34M
52-Week High
23.00000
52-Week Low
8.20000
Average Volume
0.37M
Dividend Yield
--
P/E Ratio
--
Market Capitalization540.34M52-Week High23.0000052-Week Low8.20000Average Volume0.37MDividend Yield--P/E Ratio--What does the Iteos Therapeutics Inc do?
We are a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of highly differentiated immuno-oncology therapeutics for patients. We leverage our deep understanding of the tumor microenvironment and immunosuppressive pathways to design novel product candidates with an aim to improve the clinical benefit of oncology therapies. --- We were incorporated in October 2019 under the laws of the State of Delaware. Our principal executive offices are located at 139 Main Street, Cambridge, MA 02142, and our telephone number is (339) 217-0162. We have one subsidiary located in Belgium, iTeos Belgium SA, which was incorporated in August 2011 under the laws of Belgium. Our website address is www.iteostherapeutics.com.
Read More
How much money does Iteos Therapeutics Inc make?
News & Events about Iteos Therapeutics Inc.
Zolmax
8 months ago
HC Wainwright reaffirmed their buy rating on shares of iTeos Therapeutics (NASDAQ:ITOS Get Rating) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $54.00 price objective on the stock. Several other analysts have also recently issued reports on the stock. ...
Globe Newswire
11 months ago
CAMBRIDGE, Mass. and GOSSELIES, Belgium, Jan. 03, 2023 (GLOBE NEWSWIRE) -- iTeos Therapeutics, Inc. (Nasdaq: ITOS), a clinical-stage biopharmaceutical company pioneering the discovery and development of a new generation of immuno-oncology therapeutics for patients, today announced that Michel ...
Ticker Report
1 year ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 1,870,000 shares, a decrease of 7.4% from the October 31st total of 2,020,000 shares. Currently, 6.5% of the shares...
Ticker Report
1 year ago
iTeos Therapeutics, Inc. (NASDAQ:ITOS Get Rating) Director David Hallal sold 1,171 shares of the companys stock in a transaction on Thursday, June 9th. The shares were sold at an average price of $19.51, for a total value of $22,846.21. The sale was disclosed in a legal filing with ...
Frequently Asked Questions
Frequently Asked Questions
What is Iteos Therapeutics Inc share price today?
Can Indians buy Iteos Therapeutics Inc shares?
How can I buy Iteos Therapeutics Inc shares from India?
Can Fractional shares of Iteos Therapeutics Inc be purchased?
What are the documents required to start investing in Iteos Therapeutics Inc stocks?
What is today’s traded volume of Iteos Therapeutics Inc?
What is today’s market capitalisation of Iteos Therapeutics Inc?
What is the 52-Week High and Low Range of Iteos Therapeutics Inc?
What percentage is Iteos Therapeutics Inc down from its 52-Week High?
What percentage is Iteos Therapeutics Inc up from its 52-Week Low?
Current Price
$9.84
$-0.07
(-0.71%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.
Related Stocks
Sign up and dive into a whole new world of investing.
Join over 370,000 who have signed up and are using Stockal successfully already.